COVID‐19 in haematology patients: a multicentre West Midlands clinical outcomes analysis on behalf of the West Midlands Research Consortium

Morrissey, Hana; Ball, Patrick; Mandal, Anandadeep; Nevil, Alan; Paneesha, Shankara; Basu, Supratik; Karim, Farheen; Hossain, Imran; Phillips, Neil; Khawaja, Jahanzeb; Stone, Jackie; Murray, Duncan; Randall, Katie; Murthy, Vidhya; Kishore, Bhuvan; Nikolousis, Manos; Pratt, Guy; Neilson, Jeffrey R.; Pemberton, Nick; Wandroo, Farooq

doi:10.1111/bjh.17136

Cited by 2 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…18 In contrast, two independent studies on large hematology case series from the United Kingdom have advocated the continuation of anticancer therapy in such patients, as the impact of COVID-19 on these cancer cases was deemed to be less of a risk than their underlying malignancy progressing. 19,20…”

Section: Discussionmentioning

confidence: 99%

“…This retrospective study demonstrates the possibility of more severe clinical outcomes in hematological patients with COVID-19. However, other studies with contrasting findings and recommendations 4,19,20 demonstrate the need for further studies into how the severity of COVID-19 and clinical outcomes correlates to the varied immunological response of this group-which may vary substantially between individual cases. Hematological patients who have been off chemotherapy or have been on minimum immunosuppression for some time, allowing partial host immune reconstitution may manifest stronger and potentially more aberrant immune responses that may impact on their clinical severity and outcomes of COVID-19.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) seroconversion in hematology–oncology patients

Bird

Badhwar

Kennedy

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

Since the emergence of SARS‐CoV‐2 in China at the end of 2019, the virus has spread rapidly across the globe leading to millions of infections and subsequent deaths. Although the virus infects those exposed indiscriminately, there are groups in society at an increased risk of severe infection, leading to increased morbidity. Patients suffering from haematological cancers, particularly leukaemia, lymphoma and myeloma, may be one such group and previous studies have suggested that they may be at a 3‐4 times greater risk of severe COVID‐19 after SARS‐CoV‐2 infection, leading to admissions to ICU, mechanical ventilation, and death compared to those without such malignancies. Serological testing for IgG seroconversion has been extensively studied in the immunocompetent, but fewer publications have characterised this process in large series of immunocompromised patients. This study described 20 patients with haematological cancers who tested positive for SARS‐CoV‐2 via PCR with 12 of the patients receiving further serological testing. We found that of the 12 patients screened for SARS‐CoV‐2 IgG antibodies, only 2 (16.6%) were able to generate an immune response to the infection. Yet despite this low seroconversion rate in this cohort, none of these patients died or became particularly unwell with COVID‐19 or its related complications. This article is protected by copyright. All rights reserved.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) seroconversion in hematology–oncology patients

Bird

Badhwar

Kennedy

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

Primary Arterial Hypertension and Drug-Induced Hypertension in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

The impact of primary arterial hypertension (HTN) in myeloproliferative neoplasms (MPNs) remains unclear, with scant literature available, mostly focusing on cardiovascular risk factors as a singular entity or on organ-specific HTN. Furthermore, available studies reporting findings on drug-induced HTN in MPNs report varying and contradictory findings. In consideration of the above, this study set out to systematically review the available literature and shed light on the occurrence of HTN in MPNs, its association with thrombosis, as well as the drugs used in MPN management that could increase blood pressure. The literature search yielded 598 potentially relevant records of which 315 remained after the duplicates (n = 283) were removed. After we screened the titles and the abstracts of these publications, we removed irrelevant papers (n = 228) and evaluated the full texts of 87 papers. Furthermore, 13 records did not meet the inclusion criteria and were excluded from the systematic review. Finally, a total of 74 manuscripts were entered into the qualitative synthesis and included in the present systematic review. Our systematic review highlights that HTN is the most common comorbidity encountered in MPNs, with an impact on both the occurrence of thrombosis and survival. Moreover, drug-induced HTN remains a challenge in the management of MPNs. Further research should investigate the characteristics of patients with MPNs and HTN, as well as clarify the contribution of HTN to the development of thrombotic complications, survival and management in MPNs. In addition, the relationship between clonal hematopoiesis of indeterminate potential, HTN, cardiovascular disease and MPNs requires examination in upcoming assessments.

show abstract

COVID‐19 in haematology patients: a multicentre West Midlands clinical outcomes analysis on behalf of the West Midlands Research Consortium

Abstract: CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia.

Cited by 2 publications

References 9 publications

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) seroconversion in hematology–oncology patients

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) seroconversion in hematology–oncology patients

Primary Arterial Hypertension and Drug-Induced Hypertension in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review

Contact Info

Product

Resources

About